Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 5397407, 6 pages
http://dx.doi.org/10.1155/2016/5397407
Research Article

Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China

1Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, China
2Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
3Pingguo County People’s Hospital, Guangxi 531400, China
4Department of Emergency, Affiliated Liuzhou Hospital of Guangxi Traditional Chinese Medicine University, Guangxi 545007, China

Received 18 July 2015; Revised 31 October 2015; Accepted 4 November 2015

Academic Editor: Paolo Gionchetti

Copyright © 2016 Wangxia Tong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, ) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, ). ETR (98.9% versus 90.6%, ), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, ), SVR (80.9% versus 65.6%, ), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, ) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks.